Fig. 1 · Structure

Documents & Downloads

Pomalidomide (CC-4047)

Cat. No. A10743 CAS 19171-19-8

TNF-alpha inhibitor

Pomalidomide is a derivative of thalidomide and acts as an immunomodulator.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
TNF-α (PBMCs) 13 nM

Cellular Effect

Cell Line Activity Value Description Reference
A-375 IC50 > 10 μM Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 33256948]
B16-F10 IC50 > 10 μM Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 33256948]
BXPC-3 IC50 ≤ 30 μM Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay [PMID: 33506674]
JeKo-1 IC50 > 20000 nM Antiproliferative activity against human Jeko-1 cells expressing CRBN-knockout assessed as cell viability measured after 7 days by CCK-8 assay [PMID: 35635954]
JeKo-1 IC50 2617.33 nM Antiproliferative activity against human Jeko-1 cells assessed as cell viability measured after 7 days by CCK-8 assay [PMID: 35635954]
K562 IC50 > 10 μM Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 2 days by CCK8 assay [PMID: 36306539]
K562 IC50 > 10 μM Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay [PMID: 34217059]
KARPAS-299 IC50 > 10 μM Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay [PMID: 34176264]
MCF7 IC50 > 100 μM Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay [PMID: 34864330]
MDA-MB-231 IC50 > 100 μM Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay [PMID: 34864330]
MIA PaCa-2 IC50 ≤ 30 μM Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 3 days by MTT assay [PMID: 33506674]
MM1.S IC50 21.93 nM Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 7 days by CCK-8 assay [PMID: 35635954]
MM1.S IC50 837.8 nM Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 3 days by CCK-8 assay [PMID: 35635954]
NAMALVA IC50 0.03 μM Antiproliferative activity against human NAMALWA cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs by scintillation counting [PMID: 23168019]
NCI-H929 CC50 0.035 μM Antiproliferative activity against human NCI-H929 cells after 72 hrs by WST-1 assay [PMID: 30684871]
PBMC IC50 0.013 μM Inhibition of TNF-alpha production in LPS-stimulated human PBMC preincubated for 1 hr before LPS challenge measured after 28 to 20 hrs by ELISA [PMID: 23168019]
T-cell EC50 0.008 μM Inhibition of IL-2 production in human T cells measured after 2 to 3 days by ELISA [PMID: 23168019]

17 records · Scroll to view more

In Vitro Studies

In a competitive binding assay using purified Flag-CRBN, inert opto-pomalidomide was largely ineffective at binding CRBN, in contrast to free Pomalidomide. Incubation with Pomalidomide increased p21WAF-1 expression in parental U266 cells. In MM.1SCRBN+/+ and MM.1SCRBN−/− cells, Pomalidomide reduced proliferation in a CRBN-dependent manner. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Pomalidomide binding to purified CRBN

Cell-based study · Flag-CRBN purified from human embryonic kidney (HEK) 293T cells [1]

A competitive binding assay used Flag-CRBN purified from human embryonic kidney (HEK) 293T cells. Inert opto-pomalidomide was largely ineffective at binding CRBN, in contrast to free Pomalidomide.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
competitive binding assayReported result in contrast to free pomalidomide, the inert opto-pomalidomide was largely ineffective to bind with CRBN in vitro[1]

Literature-Reported Treatment Conditions

Exposure duration
1 hour at 4°C
Reported limits
Not stated in the sentences used: dose, route, vehicle.
Methods and source locations

Compound reported in the paper: Pomalidomide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Design of opto-pomalidomide as a parent lead compound for opto-PROTAC (S9); MATERIALS AND METHODS > In vitro pulldown assays (S140); Fig. 1 legend (S156, S157)

competitive binding assay: competitive binding assay; comparator: the inert opto-pomalidomide — RESULTS > Design of opto-pomalidomide as a parent lead compound for opto-PROTAC (S9); Fig. 1 legend (S156)

Pomalidomide increases tumor suppressor expression in parental cells

Cell-based study · parental U266 cells [2]

In parental U266 cells, incubation with Pomalidomide increased expression of the tumor suppressor p21WAF-1 relative to control-treated baselines.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Expression of the tumor suppressor p21WAF-1p21WAF-1 expression 1 μℳ pomalidomide, 48 h: approximately threefold[2]

Literature-Reported Treatment Conditions

Exposure duration
48 h
Method
incubation
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Pomalidomide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > CRBN short hairpin RNA reduces the effects of lenalidomide and pomalidomide in myeloma cells (S55); Figure 2 legend (S107, S108)

Expression of the tumor suppressor p21WAF-1: Expression of the tumor suppressor p21WAF-1; comparator: control-treated baselines — Results > CRBN short hairpin RNA reduces the effects of lenalidomide and pomalidomide in myeloma cells (S55); Figure 2 legend (S107)

CRBN-Dependent Reduction in Cell Proliferation

Cell-based study · MM.1SCRBN+/+ and MM.1SCRBN−/− cells [1]

Pomalidomide was evaluated in MM.1SCRBN+/+ and MM.1SCRBN−/− cells using a CCK-8 cell viability assay. Pomalidomide reduced MM.1S cell proliferation in a CRBN-dependent manner.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CCK-8 cell viability assayReported result Pomalidomide reduces MM.1S cell proliferation in a CRBN-dependent manner.[1]

Literature-Reported Treatment Conditions

Exposure duration
72 hours
Reported limits
Not stated in the sentences used: dose, route, vehicle, control.
Methods and source locations

Compound reported in the paper: Pomalidomide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > CCK-8 cell proliferation assay (S148); Fig. 2 legend (S171, S172)

CCK-8 cell viability assay: CCK-8 cell viability assay — Fig. 2 legend (S171, S172)

In Vivo Studies

Following hematopoietic reconstitution, Bl6.SJL CD45.1+ recipient mice received Pomalidomide by oral gavage, with vehicle as the comparator. Treatment with lenalidomide, but not Pomalidomide, led to outgrowth of Trp53−/−-mutant cells in all blood cell lineages. [3]

Pomalidomide and mutant cell outgrowth following hematopoietic reconstitution

Animal study · Bl6.SJL CD45.1+ recipient mice [3]

Following hematopoietic reconstitution, Bl6.SJL CD45.1+ recipient mice received Pomalidomide by oral gavage, with vehicle as the comparator. Treatment with lenalidomide, but not Pomalidomide, led to outgrowth of Trp53−/−-mutant cells in all blood cell lineages.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PB was collected weekly and chimerism was measured using fluorescence-assisted cell sorting.Reported result pomalidomide 20 mg/kg: Treatment with lenalidomide, but not pomalidomide, led to outgrowth of Trp53−/−-mutant cells in all blood cell lineages.[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
After hematopoietic reconstitution at 8 weeks
Vehicle
10% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pomalidomide 20 mg/kgvehicle (10% DMSO)pomalidomide 20 mg/kg: Treatment with lenalidomide, but not pomalidomide, led to outgrowth of Trp53−/−-mutant cells in all blood cell lineages.[3]
Pomalidomide 20 mg/kg
Model: Bl6.SJL CD45.1+ recipient mice
Methods and source locations

Compound reported in the paper: Pomalidomide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Competitive BM transplantation and thalidomide analog treatment (S27, S28); Results > Trp53 mutation confers a selective advantage on HSPCs in the presence of lenalidomide therapy (S90, S91, S94); Figure 3. legend (S131)

PB was collected weekly and chimerism was measured using fluorescence-assisted cell sorting.: PB was collected weekly and chimerism was measured using fluorescence-assisted cell sorting.; comparator: vehicle (10% DMSO) — Results > Trp53 mutation confers a selective advantage on HSPCs in the presence of lenalidomide therapy (S91, S94); Figure 3. legend (S131)

Pomalidomide 20 mg/kg · Methods > Competitive BM transplantation and thalidomide analog treatment (S28); Results > Trp53 mutation confers a selective advantage on HSPCs in the presence of lenalidomide therapy (S91, S94)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 19171-19-8
Applications TNF-alpha inhibitor
Formula C13H11N3O4
Molecular Weight 273.2
Synonyms Actimid; CC-4047
SMILES
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 50 mg/mL (182.98 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
2 mg/mL
Vehicle
2% DMSO+30% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Liu J, Chen H, Ma L, et al. Light-induced control of protein destruction by opto-PROTAC. Sci Adv (2020). PMID: 32128407 DOI: 10.1126/sciadv.aay5154 Source material
  2. [2] Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012). PMID: 22552008 DOI: 10.1038/leu.2012.119 Source material
  3. [3] Sperling AS, Guerra VA, Kennedy JA, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood (2022). PMID: 35512188 DOI: 10.1182/blood.2021014956 Source material

Added to your cart

View Cart Checkout
Loading...